Profund Advisors LLC Incyte Corp Transaction History

Profund Advisors LLC

$2.59 Billion
Q3 2024

A detailed history of Profund Advisors LLC transactions in Incyte Corp stock. As of the latest transaction made, Profund Advisors LLC holds 53,037 shares of INCY stock, worth $3.74 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

53,037

Previous 52,788 0.47%

Holding current value

$3.74 Million

Previous $3.2 Million 9.53%

% of portfolio

0.14%

Previous 0.12%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$57.33 - $68.61 $14,275 - $17,083	249 Added 0.47%	53,037 $3.51 Million
Q2 2024 Aug 13, 2024	BUY	$51.18 - $63.75 $1.37 Million - $1.71 Million	26,803 Added 103.15%	52,788 $3.2 Million
Q1 2024 May 08, 2024	SELL	$56.55 - $66.59 $175,078 - $206,162	-3,096 Reduced 10.65%	25,985 $1.48 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $175,309 - $215,742	3,361 Added 13.07%	29,081 $1.83 Million
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $80,415 - $91,774	-1,392 Reduced 5.13%	25,720 $1.49 Million
Q2 2023 Aug 10, 2023	BUY	$60.95 - $75.51 $430,063 - $532,798	7,056 Added 35.18%	27,112 $1.69 Million
Q1 2023 May 11, 2023	SELL	$70.23 - $86.01 $111,455 - $136,497	-1,587 Reduced 7.33%	20,056 $1.45 Million
Q4 2022 Feb 02, 2023	BUY	$67.18 - $84.11 $30,029 - $37,597	447 Added 2.11%	21,643 $1.74 Million
Q3 2022 Nov 04, 2022	SELL	$66.18 - $82.86 $91,063 - $114,015	-1,376 Reduced 6.1%	21,196 $1.41 Million
Q2 2022 Aug 01, 2022	SELL	$66.18 - $83.18 $153,339 - $192,728	-2,317 Reduced 9.31%	22,572 $1.72 Million
Q1 2022 May 10, 2022	SELL	$66.02 - $79.71 $160,890 - $194,253	-2,437 Reduced 8.92%	24,889 $1.98 Million
Q4 2021 Feb 08, 2022	SELL	$63.34 - $74.11 $1.54 Million - $1.8 Million	-24,243 Reduced 47.01%	27,326 $2.01 Million
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $31,794 - $38,901	463 Added 0.91%	51,569 $3.55 Million
Q2 2021 Aug 12, 2021	SELL	$79.87 - $87.53 $115,651 - $126,743	-1,448 Reduced 2.76%	51,106 $4.3 Million
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $26,302 - $34,773	-346 Reduced 0.65%	52,554 $4.27 Million
Q4 2020 Feb 09, 2021	BUY	$80.74 - $97.7 $305,923 - $370,185	3,789 Added 7.72%	52,900 $4.6 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $414,205 - $534,080	-4,869 Reduced 9.02%	49,111 $4.41 Million
Q2 2020 Aug 03, 2020	BUY	$74.18 - $108.93 $512,954 - $753,250	6,915 Added 14.69%	53,980 $5.61 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $954,333 - $1.3 Million	-15,105 Reduced 24.3%	47,065 $3.45 Million
Q4 2019 Feb 18, 2020	BUY	$73.04 - $95.72 $470,304 - $616,341	6,439 Added 11.55%	62,170 $5.43 Million
Q3 2019 Nov 12, 2019	SELL	$72.82 - $86.52 $206,007 - $244,765	-2,829 Reduced 4.83%	55,731 $4.14 Million
Q2 2019 Aug 13, 2019	SELL	$73.52 - $88.7 $298,270 - $359,855	-4,057 Reduced 6.48%	58,560 $4.98 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $91,526 - $126,964	1,440 Added 2.35%	62,617 $5.39 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $882,472 - $1.06 Million	-15,085 Reduced 19.78%	61,177 $3.89 Million
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $416,627 - $500,829	6,747 Added 9.71%	76,262 $5.27 Million
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $209,993 - $289,814	-3,451 Reduced 4.73%	69,515 $4.66 Million
Q1 2018 May 14, 2018	SELL	$83.06 - $100.98 $403,588 - $490,661	-4,859 Reduced 6.24%	72,966 $6.08 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $568,564 - $708,578	-6,077 Reduced 7.24%	77,825 $7.37 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $634,925 - $804,316	5,817 Added 7.45%	83,902 $9.8 Million
Q2 2017 Aug 11, 2017	BUY	N/A	78,085	78,085 $9.83 Million

Others Institutions Holding INCY

# of Institutions

645

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Incyte Corp Transaction History